Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
ATM Gene Mutation: early-phase trial registry
4 of 7 indexed ATM Gene Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
ATM Gene Mutation: 7 US clinical trials tracked, 4 recruiting.
ATM Gene Mutation is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Pamela Munster, running 1 of these trials.
Enrollment posture brief
Registry condition atm-gene-mutation
OPEN 4 | RECR 57% | LATE 0 | EARLY 5 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
ATM Gene Mutation lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for ATM Gene Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
ATM Gene Mutation is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of ATM Gene Mutation trials is spread across many organizations.
Pamela Munster accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical ATM Gene Mutation enrolment sits around 114 participants.
Median target enrolment is 114 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
ATM Gene Mutation research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
Memorial Sloan Kettering Cancer Center
NCT05420064
Prostate Cancer Genetic Risk Evaluation and Screening Study
Massachusetts General Hospital
NCT05129605
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
NCT05694715
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Pamela Munster
NCT06177171
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
M.D. Anderson Cancer Center
NCT02286687
Olaparib In Metastatic Breast Cancer
Beth Israel Deaconess Medical Center
NCT03344965
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Marc Dall'Era, MD
NCT04030559
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on ATM Gene Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on ATM Gene Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this ATM Gene Mutation page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 ATM Gene Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pamela Munster sponsors the most ATM Gene Mutation trials on record, review their full trial history before evaluating a specific study. See Pamela Munster's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ATM Gene Mutation condition card totals 7 registered trials; most-linked intervention Niraparib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.